Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Glenview Trust co

Glenview Trust co lessened its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 357,562 shares of the medical research company's stock after selling 57,982 shares during the quarter. Glenview Trust co owned approximately 0.06% of Edwards Lifesciences worth $26,470,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Gallacher Capital Management LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $222,000. Natixis Advisors LLC grew its holdings in shares of Edwards Lifesciences by 51.9% during the fourth quarter. Natixis Advisors LLC now owns 288,443 shares of the medical research company's stock worth $21,353,000 after buying an additional 98,554 shares in the last quarter. Frank Rimerman Advisors LLC grew its holdings in shares of Edwards Lifesciences by 25.9% during the fourth quarter. Frank Rimerman Advisors LLC now owns 6,766 shares of the medical research company's stock worth $501,000 after buying an additional 1,392 shares in the last quarter. Van Strum & Towne Inc. grew its holdings in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Van Strum & Towne Inc. now owns 7,134 shares of the medical research company's stock worth $528,000 after buying an additional 326 shares in the last quarter. Finally, Midwest Professional Planners LTD. grew its holdings in shares of Edwards Lifesciences by 6.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 36,784 shares of the medical research company's stock worth $2,723,000 after buying an additional 2,343 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Remove Ads

Edwards Lifesciences Stock Up 0.0 %

Shares of EW traded up $0.01 during mid-day trading on Thursday, hitting $70.91. 4,052,921 shares of the company's stock were exchanged, compared to its average volume of 4,591,142. The company has a market cap of $41.69 billion, a price-to-earnings ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's 50-day moving average is $71.54 and its 200-day moving average is $70.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,303 shares of company stock worth $3,715,776. Insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EW shares. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Barclays upped their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Finally, Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.